| Name | AZD7507 |
| Description | AZD7507 is a CSF-1R inhibitor with an IC50 of 32 nM. AZD7507 has antitumor activity. |
| In vitro | AZD7507 inhibits the proliferation of 3T3 cells engineered to express CSF-1R and stimulated with CSF-1. It shows inhibitory activity against hERG and NaV1.5, with IC50s of >30 and 26 μM[1]. |
| In vivo | Xenografted mice were given liposomal clodronate (Lipclod) to selectively deplete phagocytic macrophages; AZD7507 to inhibit the activation of CSF receptor 1 (CSFR1), thereby preventing monocyte differentiation into macrophages; or appropriate vehicle alone[2]. In Lipclod-, GW2580-, and AZD7507-treated mice, we observed a significant decrease the number of CD68+ macrophages in the xenografted. Mice with CC-LP-1 and SNU-1079, but not WITT-1, xenografts demonstrated both reduced tumor volume and mass after treatment with Lipclod, GW2580, and AZD7507. Furthermore, of the 8 SNU-1079 xenografts that were palpable at 3 weeks, only 4 from the GW2580 group and 6 from the AZD7507 group were large enough to recover at week 6, as they were no longer palpable and too small to detect. In the CC-LP-1 group, only 3 of the 8 tumors were detectable at 6 weeks. (In the WITT-1 line, 7 xenografts were recovered from the GW2580 and 8 from the AZD7507 group.) Depletion of macrophages using Lipclod, GW2580, or AZD7507 in all 3 xenografted lines resulted in a reduction in murine Wnt7b expression at the mRNA level[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (220.02 mM), Sonication is recommended.
|
| Keywords | Inhibitor | AZD7507 | CSF-1R | CSF1R | CSF-1 receptor | AZD 7507 | AZD-7507 | c-Fms | inhibit | colony stimulating factor 1 receptor |
| Inhibitors Related | Phenytoin sodium | Lidocaine Hydrochloride hydrate | Lidocaine | Valproic Acid | Lidocaine hydrochloride | L-Aspartic aicd sodium | Mebeverine hydrochloride | Neratinib | Amitriptyline hydrochloride | Riluzole | Benzocaine | Nefopam hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
United States
